489 related articles for article (PubMed ID: 32594815)
1. The immunotherapy revolution in genitourinary malignancies.
U Gandhy S; Madan RA; Aragon-Ching JB
Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
[TBL] [Abstract][Full Text] [Related]
2. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in genitourinary malignancies.
Mehta K; Patel K; Parikh RA
J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
[TBL] [Abstract][Full Text] [Related]
4. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.
Dallos MC; Drake CG
Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
Gaynor N; Crown J; Collins DM
Semin Cancer Biol; 2022 Feb; 79():44-57. PubMed ID: 32623044
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
8. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
9. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Advanced Lung Cancer.
Huang J; Reckamp KL
Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
[TBL] [Abstract][Full Text] [Related]
11. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
[TBL] [Abstract][Full Text] [Related]
12. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in genitourinary cancers: achievements and perspectives.
Xylinas E; Roumiguié M; Sargos P
World J Urol; 2021 May; 39(5):1317. PubMed ID: 34003335
[No Abstract] [Full Text] [Related]
14. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
17. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
[TBL] [Abstract][Full Text] [Related]
18. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy advances in uro-genital malignancies.
Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
[TBL] [Abstract][Full Text] [Related]
20. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
